BR112017022604A2 - composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação - Google Patents

composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação

Info

Publication number
BR112017022604A2
BR112017022604A2 BR112017022604-9A BR112017022604A BR112017022604A2 BR 112017022604 A2 BR112017022604 A2 BR 112017022604A2 BR 112017022604 A BR112017022604 A BR 112017022604A BR 112017022604 A2 BR112017022604 A2 BR 112017022604A2
Authority
BR
Brazil
Prior art keywords
compound
combination
pharmaceutical composition
compounds
rip2 kinase
Prior art date
Application number
BR112017022604-9A
Other languages
English (en)
Inventor
N. Casillas Linda
David Harling John
Hussain Miah Afjal
David RACKHAM Mark
Edward David Smith Ian
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of BR112017022604A2 publication Critical patent/BR112017022604A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se a compostos, composições, combinações e medicamentos contendo ditos compostos e processos para sua preparação. a invenção também se refere ao uso de ditos compostos, combinações, composições e medicamentos, por exemplo, como inibidores da atividade da quinase rip2, incluindo degradar quinase rip2, o tratamento de doenças e condições mediadas pela quinase rip2, em particular para o tratamento de doenças ou condições inflamatórias.
BR112017022604-9A 2015-04-22 2016-04-20 composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação BR112017022604A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1506872.9 2015-04-22
GBGB1506872.9A GB201506872D0 (en) 2015-04-22 2015-04-22 Novel compounds
PCT/US2016/028332 WO2016172134A2 (en) 2015-04-22 2016-04-20 Novel compounds

Publications (1)

Publication Number Publication Date
BR112017022604A2 true BR112017022604A2 (pt) 2018-07-17

Family

ID=53299021

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017022604-9A BR112017022604A2 (pt) 2015-04-22 2016-04-20 composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação

Country Status (21)

Country Link
US (2) US10435391B2 (pt)
EP (1) EP3286169B1 (pt)
JP (1) JP2018513867A (pt)
KR (1) KR20170139096A (pt)
CN (1) CN107709305B (pt)
AU (1) AU2016252404B2 (pt)
BR (1) BR112017022604A2 (pt)
CA (1) CA2983414A1 (pt)
CL (1) CL2017002650A1 (pt)
CO (1) CO2017011851A2 (pt)
CR (1) CR20170478A (pt)
EA (1) EA033343B1 (pt)
ES (1) ES2841548T3 (pt)
GB (1) GB201506872D0 (pt)
HK (1) HK1243410A1 (pt)
IL (1) IL255067A0 (pt)
MX (1) MX2017013556A (pt)
PE (1) PE20180044A1 (pt)
PH (1) PH12017501921A1 (pt)
SG (1) SG11201708311UA (pt)
WO (1) WO2016172134A2 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117736134A (zh) 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10071164B2 (en) * 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
BR112017019751A2 (pt) 2015-03-18 2018-05-29 Arvinas Inc composto bifuncional, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou um distúrbio, e para degradar uma proteína alvo em uma célula
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
JP2019514878A (ja) * 2016-04-20 2019-06-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｉｐｋ２阻害剤を含むコンジュゲート
CA3087528C (en) 2016-09-15 2024-01-30 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
KR102173463B1 (ko) 2016-10-11 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
KR20190082989A (ko) 2016-12-01 2019-07-10 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
AU2017382406A1 (en) 2016-12-23 2019-04-18 Arvinas Operations, Inc. EGFR proteolysis targeting chimeric molecules and associated methods of use
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
MX2019007649A (es) 2016-12-23 2019-09-10 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
CN112218859A (zh) 2018-04-04 2021-01-12 阿尔维纳斯运营股份有限公司 蛋白水解调节剂及相关使用方法
JPWO2020027225A1 (ja) 2018-07-31 2021-11-11 ファイメクス株式会社 複素環化合物
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
CN112638905A (zh) * 2018-08-28 2021-04-09 南京明德新药研发有限公司 作为rip2激酶抑制剂的喹唑啉类衍生物
CN113677668A (zh) 2019-01-30 2021-11-19 蒙特利诺治疗公司 用于雄激素受体靶向泛素化的双官能化合物和方法
US11547759B2 (en) 2019-01-30 2023-01-10 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
US20220387906A1 (en) 2019-03-21 2022-12-08 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
SG11202109587TA (en) 2019-03-21 2021-10-28 Codiak Biosciences Inc Extracellular vesicle conjugates and uses thereof
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
JP2021024787A (ja) 2019-07-31 2021-02-22 ファイメクス株式会社 複素環化合物
JPWO2021020585A1 (pt) 2019-07-31 2021-02-04
TW202136240A (zh) 2019-12-19 2021-10-01 美商亞文納營運公司 用於靶向降解雄激素受體之化合物及方法
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2022061348A1 (en) * 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022197862A1 (en) * 2021-03-17 2022-09-22 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2023180388A1 (en) 2022-03-24 2023-09-28 Glaxosmithkline Intellectual Property Development Limited 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
CN115869308B (zh) * 2022-12-30 2024-03-26 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种小分子化合物在制备抗结直肠癌药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4541882B2 (ja) * 2002-07-02 2010-09-08 ノバルティス アーゲー Ｓｍａｃタンパク質のアポトーシスタンパク質阻害物質（ｉａｐ）との結合に対するペプチド阻害剤
AU2005271831A1 (en) * 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
NZ580468A (en) * 2007-04-13 2012-02-24 Univ Michigan Diazo bicyclic smac mimetics and the uses thereof
MX2009011783A (es) 2007-04-30 2009-12-04 Genentech Inc Inhibidores de iap.
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US8815927B2 (en) 2009-10-23 2014-08-26 The Regents Of The University Of Michigan Bivalent diazo bicyclic Smac mimetics and the uses thereof
ES2552977T3 (es) 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
CA2829131C (en) * 2011-03-04 2018-11-20 Glaxosmithkline Intellectual Property (No.2) Limited Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
CN117736134A (zh) 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
US8883771B2 (en) 2012-08-23 2014-11-11 The Regents Of The University Of Michigan Bivalent inhibitors of IAP proteins and therapeutic methods using the same
TWI592417B (zh) * 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) * 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
US9603889B2 (en) 2012-10-02 2017-03-28 Bristol-Myers Squibb Company IAP antagonists
MX2015007053A (es) 2012-12-11 2015-09-28 Hoffmann La Roche Compuestos dimericos.
WO2014128622A1 (en) 2013-02-21 2014-08-28 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
KR20210132233A (ko) 2014-04-14 2021-11-03 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
WO2015177326A1 (en) 2014-05-23 2015-11-26 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
KR20170044144A (ko) 2014-09-05 2017-04-24 메르크 파텐트 게엠베하 암 치료를 위한 인돌아민-2,3-디옥시게나제(ido) 길항제로서 시클로헥실-에틸 치환된 디아자- 및 트리아자-트리시클릭 화합물
EA039043B1 (ru) 2015-04-22 2021-11-25 Райджел Фармасьютикалз, Инк. Пиразольные соединения и способ получения и применения данных соединений
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
TW201642860A (zh) 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201516243D0 (en) * 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
JP2019514878A (ja) * 2016-04-20 2019-06-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｉｐｋ２阻害剤を含むコンジュゲート

Also Published As

Publication number Publication date
ES2841548T3 (es) 2021-07-08
GB201506872D0 (en) 2015-06-03
KR20170139096A (ko) 2017-12-18
AU2016252404A1 (en) 2017-12-07
MX2017013556A (es) 2018-08-01
AU2016252404B2 (en) 2018-07-26
CL2017002650A1 (es) 2018-03-16
WO2016172134A2 (en) 2016-10-27
US10435391B2 (en) 2019-10-08
CN107709305B (zh) 2020-09-29
SG11201708311UA (en) 2017-11-29
CN107709305A (zh) 2018-02-16
EA033343B1 (ru) 2019-09-30
WO2016172134A3 (en) 2016-12-01
CA2983414A1 (en) 2016-10-27
EP3286169A2 (en) 2018-02-28
CO2017011851A2 (es) 2018-02-09
EP3286169A4 (en) 2018-11-21
JP2018513867A (ja) 2018-05-31
PE20180044A1 (es) 2018-01-15
US20180134688A1 (en) 2018-05-17
EP3286169B1 (en) 2020-10-07
US20190382381A1 (en) 2019-12-19
CR20170478A (es) 2018-01-22
PH12017501921A1 (en) 2018-03-19
EA201792047A1 (ru) 2018-04-30
IL255067A0 (en) 2017-12-31
HK1243410A1 (zh) 2018-07-13

Similar Documents

Publication Publication Date Title
BR112017022604A2 (pt) composto, composição farmacêutica, uso de um composto e de uma combinação, e, combinação
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX2017014035A (es) Formas solidas novedosas.
DOP2016000253A (es) Nuevos compuestos
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112016007329A2 (pt) composto, composição farmacêutica, e, método para tratamente de uma condição ou doença mediada por hsf1
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112017020053A2 (pt) novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo
BR112017013031A2 (pt) derivados de imidazopiridazina ligados à heterociclila como inibidores de pi3kbeta
BR112016029619A2 (pt) novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112017003227A2 (pt) composto, composição farmacêutica e uso de um composto
BR112017003881A2 (pt) derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak
TR201908937T4 (tr) P38 MAP kinazı inhibe eden indanil üre bileşikleri.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 239/86 , C07D 403/12 , C07D 207/09

Ipc: C07D 403/12 (2006.01), A61K 31/4725 (2006.01), A61

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements